In addition, 13 (72%) of the 18 patients with MDS-EB or sAML had at least one mutation in a High-Molecular-Risk (HMR) gene (TP53, RUNX1, ASXL1, ETV6, EZH2). This evidence concerns the gene TP53 and epidermolysis bullosa.